Payment overview · 2025
General Payments
$177.80
10 reported records · 5 companies
Healthcare provider profile · identity verified
Brett Muha, MD
Allopathic & Osteopathic Physicians|Family Medicine · HAZARD, KY · NPI 1174547210
Verified facts
What the public records show
CMS Open Payments records show Brett Muha, MD received $177.80 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 37.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.56 | 37.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.71 | 35.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.64 | 9.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.57 | 9.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.32 | 8.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $177.80 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.71 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.71 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.25 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.25 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 235 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
196 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
235 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1039 | 277 |
| Pantoprazole Sodium | Pantoprazole Sodium | 683 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 641 | 137 |
| Gabapentin | Gabapentin | 589 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 564 | 137 |
| Metoprolol Tartrate | Metoprolol Tartrate | 553 | 151 |
| Lisinopril | Lisinopril | 477 | 137 |
| Losartan Potassium | Losartan Potassium | 416 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 349 | 96 |
| Famotidine | Famotidine | 324 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 299 | 77 |
| Fluticasone Propionate | Fluticasone Propionate | 288 | 104 |
| Metformin Hcl | Metformin Hcl | 288 | 83 |
| Potassium Chloride | Potassium Chloride | 287 | 72 |
| Hydralazine Hcl | Hydralazine Hcl | 285 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 284 | 61 |
| Montelukast Sodium | Montelukast Sodium | 280 | 83 |
| Furosemide | Furosemide | 276 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 249 | 61 |
| Tramadol Hcl | Tramadol Hcl | 247 | 54 |
| Eliquis | Apixaban | 235 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 235 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 224 | 60 |
| Omeprazole | Omeprazole | 218 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 213 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 213 | 55 |
| Buspirone Hcl | Buspirone Hcl | 203 | 52 |
| Ozempic | Semaglutide | 196 | 36 |
| Simvastatin | Simvastatin | 175 | 45 |
| Farxiga | Dapagliflozin Propanediol | 164 | 39 |
| Ondansetron Hcl | Ondansetron Hcl | 158 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 52 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 148 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 141 | 28 |
| Sertraline Hcl | Sertraline Hcl | 139 | 34 |
| Atenolol | Atenolol | 124 | 28 |
| Glipizide Er | Glipizide | 124 | 26 |
| Januvia | Sitagliptin Phosphate | 124 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 36 |
| Ezetimibe | Ezetimibe | 116 | 30 |
| Jardiance | Empagliflozin | 113 | 33 |
| Carvedilol | Carvedilol | 111 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 111 | 33 |
| Clonidine Hcl | Clonidine Hcl | 104 | 35 |
| Irbesartan | Irbesartan | 103 | 20 |
| Trazodone Hcl | Trazodone Hcl | 102 | 33 |
| Bupropion Xl | Bupropion Hcl | 101 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 98 | 29 |
| Finasteride | Finasteride | 96 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 96 | 24 |
| Allopurinol | Allopurinol | 94 | 34 |
| Clonazepam | Clonazepam | 94 | 14 |
| Meloxicam | Meloxicam | 92 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 21 |
| Baclofen | Baclofen | 83 | 23 |
| Mounjaro | Tirzepatide | 83 | 15 |
| Pregabalin | Pregabalin | 81 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 80 | 18 |
| Metformin Hcl Er | Metformin Hcl | 79 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 11 |
| Ibuprofen | Ibuprofen | 78 | 34 |
| Meclizine Hcl | Meclizine Hcl | 78 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 18 |
| Nifedipine Er | Nifedipine | 75 | 25 |
| Propranolol Hcl | Propranolol Hcl | 73 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 70 | 15 |
| Fenofibrate | Fenofibrate | 70 | 20 |
| Spironolactone | Spironolactone | 70 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 67 | 21 |
| Repatha Sureclick | Evolocumab | 67 | 12 |
| Topiramate | Topiramate | 67 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 18 |
| Nystatin | Nystatin | 66 | 40 |
| Alendronate Sodium | Alendronate Sodium | 65 | 26 |
| Levetiracetam | Levetiracetam | 65 | 15 |
| Donepezil Hcl | Donepezil Hcl | 64 | 18 |
| Prednisone | Prednisone | 64 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 11 |
| Naproxen | Naproxen | 59 | 22 |
| Fluconazole | Fluconazole | 58 | 38 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 57 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 57 | suppressed |
| Trulicity | Dulaglutide | 56 | 13 |
| Celecoxib | Celecoxib | 53 | 12 |
| Synthroid | Levothyroxine Sodium | 53 | 17 |
| Vascepa | Icosapent Ethyl | 53 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | suppressed |
| Glipizide | Glipizide | 51 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Cephalexin | Cephalexin | 47 | 32 |
| Valsartan | Valsartan | 46 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Alprazolam | Alprazolam | 43 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 43 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 14 |
| Levemir Flexpen | Insulin Detemir | 42 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 42 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 41 | 32 |
| Lansoprazole | Lansoprazole | 40 | suppressed |
| Lorazepam | Lorazepam | 40 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 12 |
| Bumetanide | Bumetanide | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 20 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 39 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 36 | 36 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 17 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 13 |
| Cefdinir | Cefdinir | 32 | 29 |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 30 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 30 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Azithromycin | Azithromycin | 29 | 23 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 14 |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Lactulose | Lactulose | 24 | 14 |
| Lidocaine | Lidocaine | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 11 |
| Primidone | Primidone | 22 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 21 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 11 |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Daptomycin | Daptomycin | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Prevacid | Lansoprazole | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $177.80 · 10 records | PFIZER INC. | ABRYSVO, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, NURTEC ODT, PREVNAR 20, QULIPTA, UBRELVY, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error